569 Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer and most often occurs in the setting of cirrhosis. Patients (pts) with advanced HCC are not eligible for curative intent therapies such as ablation, surgical resection, or liver transplantation. For the past five years, immune checkpoint inhibitor (ICI)-based systemic therapy regimens have been the mainstay of first-line treatment for pts with advanced HCC. Most trials assessing ICI-containing regimens, including IMBRAVE150 and HIMALAYA, excluded pts with Child-Pugh (CP) scores worse than A. Unfortunately, fewer than half of pts maintain a CP A score at the time of HCC diagnosis and referral to medical oncology. Real-world data on CP scores of patients undergoing ICI-based therapy for advanced HCC at the time of medical oncology referral and treatment start are lacking. Methods: Pts who initiated treatment with either atezolizumab plus bevacizumab (A+B) or durvalumab plus tremelimumab (D+T) in the Ochsner Health system between 1/1/20 and 12/31/23 were included in this analysis. CP scores were calculated at the time of their initial medical oncology visit and again at the time of their first systemic therapy cycle. Pt demographics and clinical outcomes were analyzed. Results: 200 pts were identified in this study, 159 of whom (79.5%) were male. Median age at treatment start was 66.8 years. 117 pts (58.5%) were Caucasian and 63 pts (31.5%) were African American (AA). 152 and 48 pts received A+B and D+T, respectively. At the time of first medical oncology visit, 58 pts (29%) were classified as CP B (n=51) or C (n=7). At the treatment start date, 82 pts (41%) were classified as CP B (n=73) or C (n=9). The median survival across all groups was 10.5 m. Median survival CP A, B, and C pts were 15.4, 7.6, and 1.6 months (m), respectively. 6-month survival rates for CP A, B, and C pts were 75.7%, 52.2%, and 0%, respectively. 12-month survival rates for CP A, B, and C pts were 58.2%, 35.1%, and 0%, respectively. There was no statistically significant difference in CP score at either time point between Caucasian and AA pts. Conclusions: Although pts with CP scores worse than A were not included in the pivotal studies that have established recent standard of care therapies for pts with advanced HCC, a significant proportion of pts being treated with ICI-based regimens have at least CP B liver disease, with a poorer prognosis in that subset of pts. Extremely poor survival rates for those with CP C scores argue against use of ICI-based treatment for these pts. In this analysis, no significant difference was observed in CP scores between Caucasian and AA pts.
Read full abstract